StoneX Group’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.9K Buy
+10,155
New +$59.4K ﹤0.01% 1573
2023
Q4
– Sell
-11,280
Closed -$42.6K – 710
2023
Q3
$42.6K Buy
+11,280
New +$74K ﹤0.01% 576

Other funds holding SPRY

StoneX Group's SPRY Position: Q3 2026 in Review

StoneX Group opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2026: 10,155 shares worth $60.9K. The stake represents ﹤0.01% of the portfolio and ranks #1573 among its holdings. This is a return to the name: StoneX Group previously reported a position in SPRY as recently as Q3 2023.

StoneX Group first reported a position in SPRY in Q3 2023 and has held it in 2 quarters since. 189 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • StoneX Group held 10,155 shares of ARS Pharmaceuticals worth $60.9K as of Q3 2026.
  • ARS Pharmaceuticals was a new StoneX Group position in Q3 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1573 holding.
  • StoneX Group first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 2 quarters since.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.